Hong Kong issues revised marketing practices code
This article was originally published in Scrip
Executive Summary
The Hong Kong Association of the Pharmaceutical Industry (HKAPI) has revised its code of pharmaceutical marketing practice, to ensure healthcare professionals receive accurate, fair and scientific-based information about medicines from pharmaceutical companies. The revisions, which became effective in April this year, align Hong Kong with the global standards set by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), which released its most recent edition of its code last January (Scrip Online, January 11th, 2007) outlining clearer guidelines for conduct, including limiting sponsorship and prohibiting the offer of cash and personal gifts. The revised Hong Kong code of practice, the 13th edition of the guidelines, became effective in April this year.
You may also be interested in...
How to leverage India: Five up-and-coming domestic players
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Active Biotech appoints CSO
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed appoints new chief commercial officer
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).